Tirzepatide is noninferior to dulaglutide with respect to a composite of death from cardiovascular (CV) causes, myocardial infarction, or stroke among patients with type 2 diabetes and atherosclerotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results